Related Experiment Video
Updated: Mar 24, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Pre-clinical assessment of A-674563 as an anti-melanoma agent
Ying Zou1, Guobiao Fan1, Xuemin Wang1
1Skin & Cosmetic Research Department, Shanghai Skin Disease Hospital, Shanghai, China.
Abstract:
The present study aims to investigate the anti-melanoma activity by an Akt1 specific inhibitor A-674563. We showed that A-674563 was anti-proliferative and cytotoxic when added to human melanoma cells (A375, WM-115 and SK-Mel-2 lines). A-674563 induced caspase-dependent apoptotic death of human melanoma cells, and its cytotoxicity was inhibited with pre-treatment of caspase inhibitors. Further, A-674563 treatment blocked Akt and its downstream S6 Kinase 1 (S6K1) activation in A375 melanoma cells. Significantly, restoring Akt-S6K1 activation via introduction of constitutively-active Akt1 (ca-Akt1) only partially attenuated A-674563's cytotoxicity against A375 cells. Further, A-674563 induced pro-apoptotic ceramide production in A375 cells. Significantly, sphingosine-1-phosphate (S1P) inhibited A-674563-induced ceramide production and subsequent A375 cell apoptosis. On the other hand, co-treatment with the glucosylceramide synthase (GCS) inhibitor PDMP or the cell permeable short-chain ceramide (C6) potentiated A-674563's cytotoxicity against A375 cells. In vivo, A-674563 oral gavage inhibited A375 xenograft growth in severe combined immunodeficiency (scid) mice. Akt inactivation, caspase-3 activation and ceramide production were also observed in A-674563-treated A375 xenografts. Together, these results suggest that A-674563 exerts potent anti-melanoma activity, involving Akt-dependent and Akt-independent mechanisms.
Insights
The Akt1 inhibitor A-674563 shows potent anti-melanoma activity by inducing apoptosis and inhibiting tumor growth. It works through both Akt-dependent and independent pathways, offering a promising therapeutic strategy for melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Melanoma is an aggressive skin cancer with limited treatment options.
- Targeting signaling pathways like Akt is a strategy for cancer therapy.
- Akt1 specific inhibitors represent a potential therapeutic avenue.
Purpose of the Study:
- To investigate the anti-melanoma activity of the Akt1 inhibitor A-674563.
- To elucidate the mechanisms underlying A-674563's anti-cancer effects.
- To evaluate the in vivo efficacy of A-674563 in melanoma models.
Main Methods:
- In vitro studies using human melanoma cell lines (A375, WM-115, SK-Mel-2).
- Assessment of proliferation, cytotoxicity, apoptosis (caspase-dependent), and signaling pathway activation (Akt, S6K1).
- In vivo studies using A375 xenografts in immunodeficient mice.
Main Results:
- A-674563 demonstrated anti-proliferative and cytotoxic effects on melanoma cells.
- The inhibitor induced caspase-dependent apoptosis and modulated Akt/S6K1 signaling.
- A-674563 inhibited melanoma xenograft growth in vivo, with observed Akt inactivation and apoptosis.
- Ceramide production was induced by A-674563, and its modulation affected cytotoxicity.
Conclusions:
- A-674563 exhibits significant anti-melanoma activity through both Akt-dependent and independent mechanisms.
- The compound induces apoptosis and inhibits tumor growth in vitro and in vivo.
- A-674563 represents a promising therapeutic agent for melanoma treatment.
